Burning Rock Biotech

Burning Rock Biotech

Biotechnology
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

$162.9M

Market Cap • 10/9/2026

2014

(12 years)

Founded

2020

(6 years ago)

IPO

NASDAQ

Listing Exchange

Flag of China

China

Country

Valuation

P/B

2,2

P/S

2,3

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

7

EPS

—

Market Cap

Market Cap

162,9M

EV

108,2M

EV/Revenue

1,5

EV/EBITDA

-11,6

EV/EBIT

-11,6

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0%

Total Yield

0%

Payout

0%

Retained Earnings

-631,7M

Profitability

Gross Margin

74,5%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

-26,9%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

10,4%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

-0,6%

CAGR Op. Income 5Y

-37,7%

CAGR Net Income 5Y

-37,2%

CAGR EPS 5Y

-37,4%

CAGR OCF 5Y

-48,5%

Leverage

N.D./EBITDA

5,8

Debt/Equity

0%

Current Ratio

3,1

Quick Ratio

2,8

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium